Street Calls of the Week
Grail Inc. (GRAL) Chief Executive Officer Robert P. Ragusa sold 7,239 shares of common stock on October 15, 2025, for $68.88, totaling $498,622. The stock has seen remarkable growth, with a 503% return over the past year and currently trades near its 52-week high of $89.57.
The transaction was executed to cover withholding taxes upon award vesting and share delivery. Following the transaction, Ragusa directly owns 727,388 shares of Grail Inc., representing a significant stake in the $2.72 billion market cap company. According to InvestingPro, technical indicators suggest the stock is currently in overbought territory.
The sale was disclosed in a Form 4 filing with the Securities and Exchange Commission. For deeper insights into GRAL’s valuation and 13 additional exclusive ProTips, visit InvestingPro.
In other recent news, Grail Inc reported its second-quarter 2025 earnings, showcasing a notable improvement in financial performance. The company posted an earnings per share of -$3.18, which exceeded the expected -$4.12, delivering a significant earnings surprise of 22.82%. Revenue for the quarter increased by 11% year-over-year, reaching $35.5 million. Additionally, Grail announced a strategic collaboration with Samsung, involving a $110 million investment from Samsung C&T and Samsung Electronics. This partnership aims to introduce Grail’s Galleri multi-cancer early detection test to key Asian markets, with Samsung C&T serving as the exclusive distributor in South Korea and potential expansion into Japan and Singapore. Furthermore, Grail is set to present initial results from its PATHFINDER 2 study at the European Society for Medical Oncology Congress. The study, conducted under an FDA-approved investigational device exemption, represents the largest interventional study of multi-cancer early detection in the U.S. These developments highlight Grail’s ongoing efforts to expand its market presence and advance its cancer detection technology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.